Search Results - "Mineur, L"

Circulating tumor cells in locally advanced pancreatic adenocarcinoma: the ancillary CirCe 07 study to the LAP 07 trial by Bidard, F.C., Huguet, F., Louvet, C., Mineur, L., Bouché, O., Chibaudel, B., Artru, P., Desseigne, F., Bachet, J.B., Mathiot, C., Pierga, J.Y., Hammel, P.

“…Pancreatic carcinoma is one of the leading causes of cancer-related mortality. At the time of diagnosis, 30% of patients present with a locally advanced…”
Get full text

Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study by Pagès, F, André, T, Taieb, J, Vernerey, D, Henriques, J, Borg, C, Marliot, F, Ben Jannet, R, Louvet, C, Mineur, L, Bennouna, J, Desrame, J, Faroux, R, Kirilovsky, A, Duval, A, Laurent-Puig, P, Svrcek, M, Hermitte, F, Catteau, A, Galon, J, Emile, J-F

“…The Immunoscore (IS), which prognostically classifies stage I-III colon cancer (CC) patients, was evaluated in the International Duration Evaluation of…”
Get full text

Tumor budding is an independent prognostic factor in stage III colon cancer patients: a post-hoc analysis of the IDEA-France phase III trial (PRODIGE-GERCOR) by Basile, D., Broudin, C., Emile, J.F., Falcoz, A., Pagès, F., Mineur, L., Bennouna, J., Louvet, C., Artru, P., Fratte, S., Ghiringhelli, F., André, T., Derangère, V., Vernerey, D., Taieb, J., Svrcek, M.

“…Histological characteristics at the invasive front may reflect tumor aggressiveness; specifically, tumor budding (Bd) is an emerging prognostic biomarker in…”
Get full text

Late toxicities and clinical outcome at 5 years of the ACCORD 12/0405-PRODIGE 02 trial comparing two neoadjuvant chemoradiotherapy regimens for intermediate-risk rectal cancer by Azria, D., Doyen, J., Jarlier, M., Martel-Lafay, I., Hennequin, C., Etienne, P., Vendrely, V., François, E., de La Roche, G., Bouché, O., Mirabel, X., Denis, B., Mineur, L., Berdah, J., Mahé, M., Bécouarn, Y., Dupuis, O., Lledo, G., Seitz, J., Bedenne, L., Gourgou-Bourgade, S., Juzyna, B., Conroy, T., Gérard, J.

“…Outcome of intermediate risk rectal cancer may be improved by the addition of oxaliplatin during 5-fluoruracil concomitant neoadjuvant chemoradiotherapy. The…”
Get full text

Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO study by Chauffert, B., Mornex, F., Bonnetain, F., Rougier, P., Mariette, C., Bouché, O., Bosset, J.F., Aparicio, T., Mineur, L., Azzedine, A., Hammel, P., Butel, J., Stremsdoerfer, N., Maingon, P., Bedenne, L.

“…The role of chemoradiation with systemic chemotherapy compared with chemotherapy alone in locally advanced pancreatic cancer (LAPC) is uncertain. One hundred…”
Get full text

Sphincter-saving surgery after neoadjuvant therapy for ultra-low rectal cancer where abdominoperineal resection was indicated: 10-year results of the GRECCAR 1 trial by Rouanet, P, Rivoire, M, Gourgou, S, Lelong, B, Rullier, E, Jafari, M, Mineur, L, Pocard, M, Faucheron, J L, Dravet, F, Pezet, D, Fabre, J M, Bresler, L, Balosso, J, Lemanski, C

“…This phase III trial included patients with ultra-low rectal adenocarcinoma that initially required abdominoperineal resection. The surgical decision was based…”
Get full text

What is the clinical benefit of preoperative chemoradiotherapy with 5FU/leucovorin for T3-4 rectal cancer in a pooled analysis of EORTC 22921 and FFCD 9203 trials: Surrogacy in question? by Bonnetain, F, Bosset, J.F, Gerard, J.P, Calais, G, Conroy, T, Mineur, L, Bouché, O, Maingon, P, Chapet, O, Radosevic-Jelic, L, Methy, N, Collette, L

“…Abstract Background Two phase III trials of neoadjuvant treatment in T3-4 rectal cancer established that adding chemotherapy (CRT) to radiotherapy (RT)…”
Get full text

PREMIUM: A French prospective multicenter observational study of factors impacting on efficacy and compliance to cetuximab treatment in first-line KRAS wild-type metastatic colorectal cancer by Mineur, L, François, E, Plassot, C, Phelip, J M, Miglianico, L, Dourthe, L M, Bonichon, N, Moreau, L, Guimbaud, R, Smith, D, Achille, E, Hervé, R, Bons, J M, Remy, S, Faroux, R, Villing, A L, Mahamat, A, Rabbia, I, Soulié, P, Baumgaertner, I, Mathé, N, Vazquez, L, Boustany, R

“…Cetuximab improves progression-free survival (PFS) and overall survival (OS) in patients with KRAS wild type (wt) metastatic colorectal cancer (mCRC). Few data…”
Get full text

A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802) by Ychou, M., Raoul, J.-L., Douillard, J.-Y., Gourgou-Bourgade, S., Bugat, R., Mineur, L., Viret, F., Becouarn, Y., Bouché, O., Gamelin, E., Ducreux, M., Conroy, T., Seitz, J.-F., Bedenne, L., Kramar, A.

“…Background: This multicenter adjuvant phase III trial evaluated the addition of irinotecan to LV5FU2 in colon cancer patients at high risk of relapse. Patients…”
Get full text

‘Folfirinox’ chemotherapy combined with contact x-ray brachytherapy 50kVp and ‘CAP50’ chemoradiotherapy aiming at organ preservation for selected intermediate distal-middle cT2-T3 rectal cancers: A feasibility study by Mitrea, D., Barbet, N., Pacé-Loscos, T., Scouarnec, C., Ben-Dhia, S., Baron, D., Mineur, L., Évesque, L., Durand-Labrunie, J., Gérard, J.-P., Baudin, G., Doyen, J.

“…The standard treatment of T2–T3 rectal adenocarcinoma is radical proctectomy by total mesorectal excision often combined with some neoadjuvant treatment. To…”
Get full text

Prognostic factors in patients treated with second-line chemotherapy for advanced gastric cancer: results from the randomized prospective phase III FFCD-0307 trial by Touchefeu, Y., Guimbaud, R., Louvet, C., Dahan, L., Samalin, E., Barbier, E., Le Malicot, K., Cohen, R., Gornet, J. M., Aparicio, T., Nguyen, S., Azzedine, A., Etienne, P. L., Phelip, J. M., Hammel, P., Chapelle, N., Sefrioui, D., Mineur, L., Lepage, C., Bouche, O.

“…Aim The aim of this study was to determine prognostic factors in patients treated with second-line therapy (L2) for locally advanced or metastatic gastric and…”
Get full text

Corrigendum to ‘Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study’: Annals of Oncology 2020; Volume 31: 921-929 by Pagès, F., André, T., Taieb, J., Vernerey, D., Henriques, J., Borg, C., Marliot, F., Ben Jannet, R., Louvet, C., Mineur, L., Bennouna, J., Desrame, J., Faroux, R., Kirilovsky, A., Duval, A., Laurent-Puig, P., Svrcek, M., Hermitte, F., Catteau, A., Galon, J., Emile, J-F.

Get full text

P-284NESC Multicenter phase II trial in the Preoperative Treatment of gastric adenocarcinoma consisting of chemotherapy using docetaxel-cisplatin-5FU + lenograstim followed by chemoradiation (RTCT) based 5FU and oxaliplatin and surgery by Mineur, L, Deplanque, G, Desseigne, F, Moureau-Zabotto, L, Boulat, O, Jalali, K, Smith, D, Obled, S, Belkacemi, M

Get full text

Withholding Anti-EGFR: Impact on outcome of RAS wild-type metastatic colorectal tumours (WAIT OR ACT): A multicentric AGEO study by Palmieri, L-J, Mineur, L, Tougeron, D, Rousseau, B J-C, Granger, V, Gornet, J-M, Smith, D, Lievre, A, Galais, M P, Racine Doat, S, Pernot, S, Bignon Bretagne, A L, Metges, J-P, Baba-Hamed, N, Hassine, M, Obled, S, Vitellius, C, Bouche, O, Vernerey, D, Coriat, R

Get full text

2024 Non-interventional study in elderly patients with metastatic colorectal cancer treated with first line bevacizumab combined to chemotherapy in real life: The CASSIOPEE Study - Interim analysis on patients’ characteristics by Francois, E, Kim, S, Deplanque, G, Smith, D, Gourgou, S, Rollot-Trad, F, Gally, S, Berthier, A, Mineur, L

Get full text

Mitomycin C with continuous fluorouracil or with cisplatin in combination with radiotherapy for locally advanced anal cancer (European Organisation for Research and Treatment of Cancer phase II study 22011-40014) by Matzinger, O, Roelofsen, F, Mineur, L, Koswig, S, Van Der Steen-Banasik, E.M, Van Houtte, P, Haustermans, K, Radosevic-Jelic, L, Mueller, R.P, Maingon, P, Collette, L, Bosset, J.F

“…Abstract Purpose To assess the feasibility and activity of radio-chemotherapy with mitomycin C (MMC) and cisplatin (CDDP) in locally advanced squamous cell…”
Get full text

FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomized phase III trial by Hebbar, M., Chibaudel, B., André, T., Mineur, L., Smith, D., Louvet, C., Dutel, J.L., Ychou, M., Legoux, J.L., Mabro, M., Faroux, R., Auby, D., Brusquant, D., Khalil, A., Truant, S., Hadengue, A., Dalban, C., Gayet, B., Paye, F., Pruvot, F.R., Bonnetain, F., Taieb, J., Brucker, P., Landi, B., Flesch, M., Carola, E., Martin, P., Vaillant, E., de Gramont, A.

“…The sequential FOLFOX7–FOLFIRI combination is not superior to FOLFOX4 in colorectal cancer patients with resectable metastases. Patients with synchronous…”
Get full text

2130 Tumour response outcomes during the first-line treatment of metastatic colorectal carcinoma (mCRC) with panitumumab + FOLFIRI by Karthaus, M, Hofheinz, R, Mineur, L, Letocha, H, Greil, R, Thaler, J, Fernebro, E, Zhang, Y, Oliner, K.S, Demonty, G, Kohne, C.H

Get full text

2167 Microsatellite status predicts BRAF V600E and KRAS exon 2 mutations prognostic value in stage III colon cancers (CC) patients treated with adjuvant FOLFOX +/- cetuximab. A post-hoc analysis of the PETACC8 trial by Taieb, J, Zaanan, A, Malicot, K. Le, Julie, C, Blons, H, Mineur, L, Tabernero, J, Mini, E, Folprecht, G, Laethem, J.L. Van, Lepage, C, Emile, J.F, Laurent-Puig, P

Get full text

Phase II randomised trial of chemoradiotherapy with FOLFOX4 or cisplatin plus fluorouracil in oesophageal cancer by Conroy, T, Yataghène, Y, Etienne, P L, Michel, P, Senellart, H, Raoul, J L, Mineur, L, Rives, M, Mirabel, X, Lamezec, B, Rio, E, Le Prisé, E, Peiffert, D, Adenis, A

“…Background: Concurrent chemoradiotherapy is a valuable treatment option for localised oesophageal cancer (EC), but improvement is still needed. A randomised…”
Get full text